-
TRUSTED AU LABORATORY
-
26 Mark Rd. Elizabeth South, SA - 5112
-
Same day delivery
Pull the syringe to:
(0.100ml)
This calculator is provided as a reference tool for research purposes only. Always follow your institution’s safety protocols when handling research compounds.
Retatrutide 20mg is a synthetic research peptide studied in relation to metabolic pathway research, incretin receptor signalling, glucagon receptor activity and body-weight regulation models.
Retatrutide is also known by the development code LY3437943. It is commonly described in research literature as a triple hormone receptor agonist because it has activity at the GIP, GLP-1 and glucagon receptors. A phase 2 trial published in the New England Journal of Medicine describes retatrutide as an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors.
This product is supplied for laboratory research use only. It is not a medicine, supplement, weight loss product, obesity treatment, body composition product, metabolic treatment or injectable product for human use.
| Product Detail | Information |
|---|---|
| Product name | Retatrutide |
| Development code | LY3437943 |
| Size | 20mg |
| Product type | Research peptide |
| Research category | Metabolic Research |
| Common research interest | GLP-1, GIP and glucagon receptor pathway research |
| Peptide type | Synthetic lipidated peptide |
| Main receptor interests | GLP-1R, GIPR and GCGR |
| Form | Lyophilised powder |
| Intended use | Laboratory research only |
| Human use | Not for human consumption, administration, weight loss or injection |
| Documentation | Certificate of Analysis should be checked before use |
| Component | Research Class | General Research Role |
| Retatrutide | Synthetic peptide | Studied as a triple hormone receptor agonist in metabolic research |
| GLP-1 receptor activity | Incretin receptor pathway | Studied in relation to glucose, satiety and metabolic signalling models |
| GIP receptor activity | Incretin receptor pathway | Studied in relation to insulinotropic and metabolic pathway research |
| Glucagon receptor activity | Glucagon pathway | Studied in relation to energy expenditure and hepatic metabolic signalling |
| Lipidated peptide design | Fatty-acid modified peptide format | Studied for extended activity and albumin-binding behaviour |
| Lyophilised peptide preparation | Freeze-dried peptide format | Supports stability before reconstitution when stored correctly |
Retatrutide is commonly listed with CAS number 2381089-83-2. Multiple chemical databases list related molecular formula records for retatrutide and its salt forms, so researchers should confirm the exact identity, salt form, purity and batch information through the supplier Certificate of Analysis rather than relying on a product name alone.
Retatrutide is studied as a triple agonist of three metabolic receptor pathways: GLP-1R, GIPR and GCGR. These pathways are commonly studied in obesity, diabetes, energy expenditure, appetite signalling, glucose regulation and metabolic disease research.
The GLP-1 receptor pathway is often studied in relation to incretin biology, glucose-dependent insulin secretion, gastric-emptying models and satiety pathway research.
The GIP receptor pathway is studied in relation to insulinotropic signalling and broader metabolic response models.
The glucagon receptor pathway is studied in relation to hepatic glucose output, lipid metabolism, energy expenditure and metabolic flexibility models.
In clinical research, retatrutide has been investigated in people with obesity and type 2 diabetes, but those studies relate to controlled investigational drug development and do not make research-use vials approved for human use.
| Research Area | Retatrutide |
| Main research category | Metabolic peptide research |
| Development code | LY3437943 |
| Common receptor focus | GLP-1R, GIPR and GCGR |
| Research pathway interest | Incretin, glucagon and energy metabolism signalling |
| Common study context | Obesity, metabolic disease and body-weight regulation research |
| Structure interest | Synthetic lipidated peptide with extended activity profile |
| Evidence limitation | Clinical research context does not make research vials approved for human use |
| Product limitation | Research use only, not approved for human use |
| Feature | Retatrutide | Tirzepatide |
| Research class | Triple hormone receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Main receptor pathways | GIP, GLP-1 and glucagon receptors | GIP and GLP-1 receptors |
| Glucagon receptor activity | Yes, part of the triple agonist research profile | Not the same triple agonist profile |
| Common research interest | Incretin, glucagon and energy expenditure models | Incretin and glucose regulation models |
| Approved medicine context | Investigational molecule in clinical development | Approved tirzepatide medicines exist, but are not equivalent to research-use products |
| Human-use claim | Not appropriate for this product | Only relevant to approved, regulated medicines |
| Strength | Product Page Positioning |
| Retatrutide 10mg | Lower-strength research vial for concentration planning |
| Retatrutide 15mg | Mid-strength research vial for metabolic pathway studies |
| Retatrutide 20mg | Higher-strength research vial for protocol-specific concentration planning |
| Retatrutide 30mg | Bulk-style research vial where higher total material is required |
| Retatrutide 60mg | Higher-volume research supply where supported by protocol and documentation |
Retatrutide strengths should be treated as product variants, not duplicate product pages. If multiple strengths are listed separately, each page should have a strength-specific title, meta description, slug and internal links to avoid SEO cannibalisation.
Retatrutide should not be promoted as having proven benefits for the human body. It should not be positioned as a weight loss injection, fat loss product, appetite suppressant, Ozempic alternative, Mounjaro alternative, body transformation product, metabolic treatment, diabetes product, anti-ageing product or injectable product.
The TGA warns that unapproved peptide products promoted online have not been assessed for safety, quality or effectiveness, and may be poorly labelled, contaminated or unsafe. Retatrutide is specifically named in recent Australian safety communications about unapproved peptide products and related adverse events.
For SEO and compliance, it is safer to discuss research pathways rather than direct human benefits.
| Common Online Claim | Safer Research-Use Wording |
| Weight loss | Studied in obesity-related clinical and metabolic research contexts |
| Fat loss | Better framed as metabolic pathway and body-weight regulation research |
| Appetite suppression | Studied in relation to incretin and central appetite signalling models |
| Ozempic alternative | Not accurate or compliant; retatrutide is an investigational triple agonist |
| Mounjaro alternative | Not appropriate; tirzepatide is a dual agonist and approved medicines are not equivalent to research vials |
| Diabetes treatment | Not an approved or appropriate product claim for research-use material |
| Body transformation | Not an approved or appropriate product claim |
| Metabolic boost | Better framed as energy expenditure and metabolic pathway research |
Retatrutide 20mg is not intended to diagnose, treat, cure or prevent any disease. It is not supplied for weight loss, fat loss, appetite control, obesity treatment, diabetes management, body transformation, bodybuilding, anti-ageing, metabolic health, performance enhancement or general wellness use.
All information on this page is provided for laboratory research and product handling context only.
There is no universal recommended dilution for Retatrutide 20mg. Dilution depends on the research protocol, required working concentration, assay design, solvent compatibility, storage method and validated laboratory procedure.
For research concentration planning only, the basic formula is:
Total peptide amount divided by diluent volume equals final concentration.
| Diluent Added to 20mg Vial | Final Concentration |
| 1mL | 20mg/mL |
| 2mL | 10mg/mL |
| 4mL | 5mg/mL |
| 5mL | 4mg/mL |
| 8mL | 2.5mg/mL |
| 10mL | 2mg/mL |
| 20mL | 1mg/mL |
These are research concentration examples only. They are not human dosing instructions and must not be used to calculate injection quantities.
Before handling Retatrutide 20mg in a laboratory setting, make sure all materials, documentation and clean handling conditions are prepared.
| Item | Purpose |
| Product vial | Contains lyophilised Retatrutide peptide |
| Certificate of Analysis | Confirms batch-level testing information |
| Suitable research-grade diluent | Used to prepare a working research solution |
| Sterile lab consumables | Helps reduce contamination risk |
| Personal protective equipment | Gloves, lab coat and eye protection |
| Alcohol wipes or approved disinfectant | Used for surface and vial-top preparation |
| Laboratory labels | Records concentration, date, batch and handler details |
| Cold storage access | Supports correct storage after preparation |
| Disposal container | Used for compliant laboratory waste disposal |
The following is a general laboratory handling framework only. Always follow the product Certificate of Analysis, supplier documentation, SDS, institutional procedures and validated research protocol.
Check the product label, batch number, Certificate of Analysis and storage requirements before handling the vial.
Use a clean laboratory workspace. Wear appropriate PPE and disinfect the bench surface, vial top and any required equipment.
If the vial has been stored cold, allow it to equilibrate according to laboratory procedure before opening or reconstitution. Avoid condensation entering the vial.
Add the selected research-grade diluent slowly down the inside wall of the vial. Avoid forceful spraying directly onto the lyophilised powder.
Gently swirl or roll the vial until the powder is dissolved. Avoid aggressive shaking, unnecessary vortexing or foaming unless a validated protocol specifically allows it.
Check the solution for cloudiness, visible particles, unusual colour changes or undissolved material. If anything appears abnormal, quarantine the vial and check supplier documentation.
Label the vial or aliquots with the product name, concentration, diluent used, date prepared, batch number and researcher initials.
Place the reconstituted solution into the required storage condition as soon as possible. Avoid unnecessary warming, cooling or repeated freeze-thaw cycles.
Some lyophilised peptide products may take time to fully hydrate. Dissolution should always be handled gently and according to laboratory protocol.
| Issue | What It May Indicate | Safer Response |
| Powder clinging to vial wall | Static or lyophilisation residue | Allow more contact time with diluent |
| Small particles remain | Incomplete hydration | Continue gentle swirling |
| Cloudy solution | Possible incompatibility or contamination | Stop and check documentation |
| Foaming | Too much agitation | Let the solution settle and avoid shaking |
| Colour change | Possible degradation or contamination | Do not continue without supplier guidance |
| Storage Factor | Guidance |
| Product form | Lyophilised powder |
| Storage condition | Follow supplier label and Certificate of Analysis |
| Light exposure | Protect from unnecessary light exposure |
| Moisture exposure | Keep sealed until use |
| Temperature changes | Avoid repeated temperature cycling |
| Handling | Minimise unnecessary opening or vial puncture |
| Storage Factor | Guidance |
| Storage condition | Follow validated research protocol |
| Labelling | Record concentration, date, diluent and batch number |
| Freeze-thaw cycles | Avoid repeated freeze-thaw exposure |
| Aliquoting | Use small research aliquots where appropriate |
| Contamination control | Use clean laboratory technique |
| Light exposure | Protect from unnecessary light exposure where required |
| Disposal | Dispose according to laboratory waste procedures |
Peptides may be sensitive to temperature, light, pH, agitation and contamination. Storage conditions should be confirmed through supplier documentation or the laboratory’s validated method.
This page does not provide human dosing, injection instructions, injection schedules or administration guidance.
Retatrutide 20mg is not supplied for human or animal administration. It is a laboratory research-use product only.
For research settings, any measured aliquots should be prepared according to the concentration required by the approved research protocol. All calculations should be checked, documented and traceable.
| Planning Item | What to Record |
| Final concentration | Total peptide amount and diluent volume |
| Working solution | Concentration used in the research protocol |
| Aliquot volume | Volume transferred into each labelled lab tube |
| Batch details | Product batch, CoA and preparation date |
| Storage location | Fridge, freezer or other controlled storage area |
| Handler details | Researcher name or initials |
| Preparation date | Date and time of reconstitution |
| Disposal date | When the aliquot should no longer be used |
Correct handling is important for research consistency, contamination control and product traceability. Most mistakes occur when products are not labelled clearly, concentration calculations are not recorded or storage conditions are not followed.
Because retatrutide is widely discussed online in relation to weight loss and GLP-1-style products, product pages should avoid wording that could be interpreted as encouraging human weight loss, appetite suppression, self-injection or obesity treatment use.
| Always | Why It Matters |
| Check the Certificate of Analysis | Confirms batch-level information |
| Use PPE | Reduces contamination and exposure risk |
| Label every vial and aliquot | Prevents mix-ups |
| Record concentration calculations | Supports traceability |
| Use clean laboratory technique | Reduces contamination risk |
| Follow institutional protocols | Keeps handling consistent and auditable |
| Store according to documentation | Helps protect peptide integrity |
| Dispose of lab waste correctly | Supports safety and compliance |
| Use research-use wording only | Reduces misleading human-use interpretation |
| Never | Why It Is Risky |
| Never use for self-injection | Product is research use only |
| Never sell or promote as a weight loss product | Creates human-use and compliance risk |
| Never make appetite suppression claims | Not an approved or appropriate product claim |
| Never describe it as Ozempic or Mounjaro | Misleading because retatrutide is a separate investigational triple agonist |
| Never compare it directly to approved obesity medicines | Misleading and clinically inappropriate |
| Never make diabetes treatment claims | Not an approved or appropriate product claim |
| Never assume purity without CoA | Batch quality must be documented |
| Never use a damaged or unlabelled vial | Identity and sterility may be uncertain |
| Never shake aggressively | May affect peptide integrity |
| Never use random solvents | May damage the peptide or alter research results |
| Never leave reconstituted product unlabelled | Creates traceability risk |
| Never rely on social media protocols | They may be inaccurate, unsafe or non-compliant |
The table below is for concentration planning only. It does not represent dosage, injection quantity or recommended administration.
| Total Vial Amount | Diluent Volume | Final Concentration |
| 20mg | 1mL | 20mg/mL |
| 20mg | 2mL | 10mg/mL |
| 20mg | 4mL | 5mg/mL |
| 20mg | 5mL | 4mg/mL |
| 20mg | 8mL | 2.5mg/mL |
| 20mg | 10mL | 2mg/mL |
| 20mg | 20mL | 1mg/mL |
If a researcher adds 4mL of suitable research-grade diluent to a 20mg vial, the resulting concentration is 5mg/mL.
This calculation is for research concentration planning only. It is not a human or animal dosing example.
Retatrutide is a synthetic research peptide also known as LY3437943. It is studied as a triple hormone receptor agonist with activity at GIP, GLP-1 and glucagon receptors.
Retatrutide is not only a GLP-1 receptor agonist. It is commonly described as a triple agonist because it is studied in relation to GLP-1, GIP and glucagon receptor pathways.
No. Tirzepatide is a dual GIP and GLP-1 receptor agonist. Retatrutide is studied as a triple GIP, GLP-1 and glucagon receptor agonist.
This research product is not approved or supplied for weight loss, obesity treatment, appetite control or human use. It should be described only as a laboratory research product.
Retatrutide is studied because GLP-1, GIP and glucagon pathways are connected to appetite signalling, glucose regulation, energy expenditure, lipid metabolism and body-weight regulation research.
A Certificate of Analysis provides batch-level testing information. It helps researchers verify product identity, purity and quality documentation before use in a research setting.
| Resource | Why It Is Useful |
| PubChem Retatrutide compound profile | Useful background on retatrutide identity and chemical data. |
| Lilly Retatrutide clinical development information | Useful background on the investigational triple hormone receptor agonist mechanism. |
| New England Journal of Medicine phase 2 retatrutide trial | Useful background on clinical research involving retatrutide in obesity-related study settings. |
Retatrutide 20mg for qualified laboratory research only. Not for human or veterinary use.
